Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Drugs in Development News & Deals for Prestwick3_000009

    Client Email Product

    Prestwick3_000009

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    57
    US DMFs Filed

    US DMFs Filed

    31
    CEP/COS Certifications

    CEP/COS Certifications

    22
    JDMFs Filed

    JDMFs Filed

    8
    Other Certificates

    Other Certificates

    10
    Other Suppliers

    Other Suppliers

    24
    API REF. PRICE (USD / KG)
    35

    API Market Place

    29
    INTERMEDIATES
    2
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    874
    Europe

    Europe

    1374
    Canada

    Canada

    235
    Australia

    Australia

    34
    South Africa

    South Africa

    161
    Uploaded Dossiers

    Uploaded Dossiers

    385
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    2,266.00

    Annual Reports

    1,023.00

    FDF Market Place

    18
    EXCIPIENTS
    373
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    4

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    3

    News

    143
    REF STANDARD

    EDQM

    3

    USP

    1

    JP

    3

    Other Listed Suppliers

    1
    SERVICES
    2
    left grey arrow
    right gray arrow
    • TABLET;ORAL - 25MG;25MG
    • TABLET;ORAL - 50MG;50MG
    • CAPSULE;ORAL - 25MG;37.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - 25MG;37.5MG
    • TABLET;ORAL - 50MG;75MG
    • TABLET;ORAL - 10MG;25MG
    • TABLET;ORAL - 5MG;12.5MG
    • TABLET;ORAL - 12.5MG;10MG
    • TABLET;ORAL - 12.5MG;20MG
    • TABLET;ORAL - 25MG;20MG
    • TABLET;ORAL - 12.5MG;100MG
    • TABLET;ORAL - 12.5MG;50MG
    • TABLET;ORAL - 25MG;100MG
    • CAPSULE;ORAL - 12.5MG
    • TABLET;ORAL - 12.5MG;150MG
    • TABLET;ORAL - 12.5MG;300MG
    • TABLET;ORAL - 12.5MG;75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - 25MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - 12.5MG;160MG
    • TABLET;ORAL - 12.5MG;320MG
    • TABLET;ORAL - 12.5MG;80MG
    • TABLET;ORAL - 25MG;160MG
    • TABLET;ORAL - 25MG;320MG
    • TABLET;ORAL - 16MG;12.5MG
    • TABLET;ORAL - 32MG;12.5MG
    • TABLET;ORAL - 32MG;25MG
    • TABLET;ORAL - 12.5MG;40MG
    • TABLET;ORAL - 12.5MG;80MG
    • TABLET;ORAL - 25MG;80MG
    • TABLET;ORAL - 12.5MG;20MG
    • TABLET;ORAL - 12.5MG;40MG
    • TABLET;ORAL - 25MG;40MG
    • TABLET, EXTENDED RELEASE;ORAL - 12.5MG;EQ 100MG TARTRATE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET, EXTENDED RELEASE;ORAL - 12.5MG;EQ 25MG TARTRATE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET, EXTENDED RELEASE;ORAL - 12.5MG;EQ 50MG TARTRATE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - EQ 150MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - EQ 150MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - EQ 300MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - EQ 300MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - EQ 10MG BASE;12.5MG;160MG
    • TABLET;ORAL - EQ 10MG BASE;25MG;160MG
    • TABLET;ORAL - EQ 10MG BASE;25MG;320MG
    • TABLET;ORAL - EQ 5MG BASE;12.5MG;160MG
    • TABLET;ORAL - EQ 5MG BASE;25MG;160MG
    • TABLET;ORAL - 25MG
    • TABLET;ORAL - 50MG
    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Zydus Receives Final Approval from The USFDA for Olmesartan Medoxomil and Hydrochlorothiazide Tablets

    Details:

    A generic combination is approved consisting of olmesartan medoxomil which blocks the vasoconstrictor effects of angiotensin II in vascular smooth muscle and hydrochlorothiazide is a diuretic that inhibits sodium chloride transport in the distal convoluted tubule.


    Lead Product(s): Olmesartan Medoxomil,Hydrochlorothiazide

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Benicar HCT-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 28, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Glenmark Pharmaceuticals Receives ANDA Approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.2...

    Details:

    ANDA Approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets generic version of Ziac is a combination of a thiazide diuretic and a beta-blocker used to treat high blood pressure (hypertension).


    Lead Product(s): Bisoprolol Fumarate,Hydrochlorothiazide

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Combination-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 27, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    Polpharma Hydrochlorothiazide

    Access Virtual Booth

    Contact Supplier

    View Presentation

    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search